Undisclosed Hsp90β-selective inhibitor
/ Grannus Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Synthetic lethality of Hsp90beta-selective inhibition with PARPi in homologous recombination repair proficient ovarian cancer
(AACR 2026)
- "Therefore, Hsp90β-selective inhibition has been proposed as safer alternative to pan-Hsp90 inhibition for cancer treatment. This presentation will contain results from mechanistic, efficacy and safety studies of the orally bioavailable and efficacious Hsp90beta-selective inhibitor in combination with a PARP inhibitor."
Synthetic lethality • Oncology • Ovarian Cancer • Solid Tumor • CDC37 • HRD • HSP90AB1
1 to 1
Of
1
Go to page
1